Research progress in effect of pelvic bone marrow-sparing intensity-modulated radiotherapy on hematologic toxicity in pelvic tumor patients after concurrent chemoradiotherapy / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
;
(6): 949-951, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-708298
ABSTRACT
Concurrent chemoradiotherapy can improve the survival rate in patients with advanced pelvic tumors.However,it also increases the incidence of hematologic toxicity and other adverse events.Patients cannot tolerate these adverse events and discontinue the therapy.Pelvic bone marrow-sparing intensity-modulated radiotherapy (PBMS-IMRT) possesses obvious advantages in reducing the radiation dose and volume of the pelvic bone marrow.In this article,comparison between PBMS-IMRT and other irradiation therapies,correlation between dosimetric parameters and hematologic toxicity and imaging methods with precise delineation of the active bone marrow were reviewed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Radiation Oncology
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS